唯捷創芯(688153.SH):L-FEM的成熟產品處於大規模量產階段
格隆匯9月6日丨有投資者向唯捷創芯(688153.SH)提問:請介紹公司接收端模組產品情況。
唯捷創芯回覆:公司銷售的接收端模組產品包括LNA Bank、L-FEM及開關等產品,其中LNA Bank通過設計優化完成了迭代更新,第三代產品已正式量產出貨,第四代產品也在研發設計中。L-FEM的成熟產品處於大規模量產階段,新一代產品已在研發驗證中;作為可與低壓版L-PAMiF模組搭配使用的接收端產品,其將在發射端產品的帶動下,開發新營收增長點,提升市場份額。
截至報吿期末,公司接收端模組的新產品DRx與DiFEM模組的研發、驗證和推廣,正按計劃進行,預計將在年末正式推出。謝謝。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.